Meth Detox Still Has No Approved Medication, Review Finds

Anyone arranging medical detox for methamphetamine runs into a gap that doesn’t exist for alcohol or opioids. The FDA has approved no medication to treat methamphetamine use disorder or to manage withdrawal from it.

A scoping review published July 7, 2026, in Substance Use & Addiction Journal maps what the evidence does support. The answer shapes how the first weeks of care should be built.

Researchers from the University of Malaya Centre for Addiction Sciences, MAHSA University, and the University of Medical Sciences and Technology in Khartoum screened 6,852 records across five databases and included 62 studies, searching from database inception through October 2025.

What Methamphetamine Withdrawal Involves

Stimulant withdrawal lacks the acute medical danger that untreated alcohol or benzodiazepine withdrawal does. There’s no seizure risk and no equivalent of delirium tremens.

The crash instead brings heavy fatigue, disrupted sleep, strong cravings and a stretch of depressed mood and flattened motivation that can run from days into weeks. The timeline remains longer and flatter than an alcohol taper, so programs built only around acute stabilization tend to discharge people too early.

Why Medical Detox Still Matters for Stimulants

Because the danger is psychiatric rather than cardiovascular or neurological, supervision looks different here. The value of a medically supervised setting during stimulant withdrawal lies in monitoring mood, managing sleep, and having clinical staff present through the window when depression and suicidal thinking tend to surface.

The second reason is diagnostic. A person presenting for stimulant care frequently has another dependence underneath it, and that changes the withdrawal plan entirely.

Medication Options and What the Evidence Shows

The review found one pharmacological combination with meaningful support. Naltrexone paired with bupropion significantly increased the share of methamphetamine-negative urine samples with 11.4% against 5.7% for placebos.

Patients receive both drugs off label for this purpose. Naltrexone is an opioid antagonist already used in alcohol and opioid use disorder, and bupropion is an antidepressant acting on dopamine and norepinephrine reuptake.

The review describes pharmacological effect sizes across the literature as generally modest, and the placebo comparison makes the ceiling clear. Most participants in those trials did not reach sustained abstinence on medication alone.

This is a different situation from medication-assisted treatment for opioid use disorder. In those cases, buprenorphine and methadone carry decades of outcome data and a defined standard of care.

A detox program treating methamphetamine should not present pharmacotherapy as settled protocol, and anyone comparing programs should ask directly what is prescribed, on what evidence, and with what monitoring.

Why Intake Screening Decides the Detox Plan

The review found polydrug use running as high as 42% in opioid use disorder cohorts, and people using multiple substances had worse treatment outcomes.

That figure carries direct operational weight for detox. Someone who arrives for methamphetamine care may also be physically dependent on opioids, alcohol, or benzodiazepines, and each of those carries its own withdrawal management requirements, some of them medically urgent. Benzodiazepine and alcohol dependence require supervised tapering.

Opioid dependence opens the door to buprenorphine or methadone, where medication-assisted treatment genuinely is the standard. A methamphetamine intake that does not screen for all three is not assessing the thing that most determines the safety of the withdrawal plan.

What Follows Withdrawal Management

Detox represents a stage of stabilization, not treatment. The review bluntly states where the strongest evidence sits. Contingency management, which provides tangible incentives for verified drug-negative tests, increased abstinence rates by 40% to 60%, outperforming every other intervention examined.

Repetitive transcranial magnetic stimulation aimed at the dorsolateral prefrontal cortex reduced cue-induced craving by 25% to 35%. Two factors shaped who responded. A variant in the gene coding for the mu-opioid receptor, OPRM1 A118G, associated with differences in treatment response.

Implementation quality comprised the other. Accordingly, authors flagged intervention fidelity and pharmacotherapy adherence as persistent problems. A program can have good evidence behind it and still fail if clinicians don’t deliver incentives as designed or patients don’t take medication consistently.

Choosing a Medical Detox Program

Ask what happens on day one and what happens on day thirty. Specifically, ask whether intake screens for opioid, alcohol, and benzodiazepine dependence, whether psychiatric assessment and mood monitoring comprise part of the stay rather than an add-on, what medication the program uses and on what basis, and whether a documented handoff into continuing care with contingency management attached occurs.

Detox.com’s directory lists medically supervised detox centers by state and city, with details on substances treated, levels of care, medication-assisted treatment availability, and insurance accepted. Call 800-996-6135(Sponsored) to learn more about your treatment options.